Affimed to Present at the Cantor Global Healthcare Conference 2024

Rhea-AI Summary

Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company, has announced its participation in the Cantor Global Healthcare Conference 2024. CEO Shawn M. Leland will engage in a fireside chat on September 17, 2024, at 8:00 a.m. EDT / 14:00 CET.

A live webcast of the presentation will be available on Affimed's website, with a 30-day replay option. Investors interested in one-on-one meetings with Affimed's management can contact their Cantor Fitzgerald representative or reach out to Alex Fudukidis at a.fudukidis@affimed.com or +1 (917) 436-8102.

This event provides an opportunity for Affimed to showcase its progress in developing therapies that harness patients' innate ability to fight cancer.

MANNHEIM, Germany, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that its Chief Executive Officer, Shawn M. Leland, PharmD, RPh, will participate in a fireside chat at the Cantor Global Healthcare Conference 2024 on Tuesday, September 17, 2024 at 8:00 a.m. Eastern Daylight Time / 14:00 Central European Time.

A live webcast of the presentation will be accessible on Affimed’s website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay of the call will be archived on Affimed’s website for 30 days after the call.

For more information on the conference or to schedule a one-on-one meeting with Affimed’s management, please contact your Cantor Fitzgerald representative or Alex Fudukidis via email at a.fudukidis@affimed.com or phone at +1 (917) 436-8102.

About Affimed N.V.
Affimed (Nasdaq: AFMD) is a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer by actualizing the untapped potential of the innate immune system. The Company’s innate cell engagers (ICE®) enable a tumor-targeted approach to recognize and kill a range of hematologic and solid tumors. ICE® are generated on the Company’s proprietary ROCK® platform which predictably generates customized molecules that leverage the power of innate immune cells to destroy tumor cells.  A number of ICE® molecules are in clinical development, being studied as mono- or combination therapy. Headquartered in Mannheim, Germany, Affimed is led by an experienced team of biotechnology and pharmaceutical leaders united by a bold vision to stop cancer from ever derailing patients’ lives. For more about the Company’s people, pipeline and partners, please visit: www.affimed.com.

Investor Relations Contact
Alexander Fudukidis
Director, Head of Investor Relations
E-Mail: a.fudukidis@affimed.com
Tel.: +1 (917) 436-8102

FAQ

When is Affimed (AFMD) presenting at the Cantor Global Healthcare Conference 2024?

Affimed (AFMD) is presenting at the Cantor Global Healthcare Conference 2024 on Tuesday, September 17, 2024, at 8:00 a.m. Eastern Daylight Time / 14:00 Central European Time.

Who will be representing Affimed (AFMD) at the Cantor Global Healthcare Conference 2024?

Shawn M. Leland, PharmD, RPh, the Chief Executive Officer of Affimed (AFMD), will be representing the company in a fireside chat at the Cantor Global Healthcare Conference 2024.

How can investors access Affimed's (AFMD) presentation at the Cantor Global Healthcare Conference 2024?

Investors can access a live webcast of Affimed's (AFMD) presentation on the company's website at https://www.affimed.com/investors/webcasts-and-corporate-presentation/. A replay will be available for 30 days after the event.

How can investors schedule a one-on-one meeting with Affimed's (AFMD) management at the conference?

Investors can schedule a one-on-one meeting with Affimed's (AFMD) management by contacting their Cantor Fitzgerald representative or reaching out to Alex Fudukidis at a.fudukidis@affimed.com or +1 (917) 436-8102.